11:10 AM EDT, 08/05/2025 (MT Newswires) -- CFRA, an independent research provider, has provided MT Newswires with the following research alert. Analysts at CFRA have summarized their opinion as follows:

After reviewing Q2 results, we maintain our target price at $28, 9.2x our 2026 EPS estimate, a discount to PFE's historical forward P/E average. We raise our 2025 EPS view to $3.07 from $2.94 and maintain our 2026 EPS estimate at $3.06. In our view, Pfizer's ( PFE ) Q2 results demonstrated better-than-expected performance across key metrics despite a complex and rapidly evolving business environment. Q2 revenues of $14.7B, up a solid 10% Y/Y, were above expectations, driven by strong growth fueled by significant increases in key products sales, including the Vyndaqel family (+21% Y/Y), Comirnaty (+95% Y/Y), Paxlovid (+71% Y/Y), and Padcev (+38% Y/Y). The company's profitability metrics also showed substantial improvement, led by the company's ongoing cost management efforts, which we believe are bearing fruit. While the policy environment remains uncertain in the near term, management's active engagement with the government, as outlined by CEO A. Bourla during the Q2 call, is positive, in our view.